CareDx Q3 2026 earnings

CDNA · 2026-10-29 16:02 AMC ET · 8-K on SEC · 10-Q on SEC

Revenue and adjusted EBITDA grew 39% and 100% year-over-year, respectively, with gross margin stable at 74% and adjusted EBITDA margin expanding to 22%.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$139.4M+39%+5.6%Ex. 99.1, income statement
EPS (GAAP)$0.37+1,133%-66.6%Ex. 99.1, income statement
EPS (adjusted)$0.70+157%-46.3%Ex. 99.1, income statement
Net income$19.3M+1,052%-82.6%Ex. 99.1, income statement
Adj. EBITDA$30.5M+100%-22.8%Ex. 99.1, income statement
Adj. EBITDA margin22%+7 pp-3 ppEx. 99.1, income statement

Revenue breakdown

SegmentActualYoYShare of revenueNote
Testing Services$119.2M+65%85.5%Includes $12M Specialty Oncology revenue
Patient and Digital Solutions$20.2M+31%14.5%—

Margins and costs

  • Gross margin 74% (prior 74%, change 0 pp)
  • Operating expenses $131.3M (+30% YoY)
  • One-offs in the quarter Business development and portfolio optimization expense: $5.5M; Acquisition related-amortization of purchased intangibles: $3.9M; Stock-based compensation expense: $9.7M
  • Effective tax rate 80% (prior-year -6%, year-to-date 80%)
  • Non-GAAP bridge Excludes stock-based compensation, acquisition-related amortization, contingent consideration, litigation settlement, business development and portfolio optimization expense, and gain on sale of lab products business.

KPIs

MetricActualPrior quarterPrior yearChange
Testing Services volume75,90058,00050,200+31% QoQ, +51% YoY
Cash and cash equivalents$250.5M$373.6M$65.4M-33% QoQ, +283% YoY
Cash flow from operations$13.0M$31.0M$9.9M-58% QoQ, +31% YoY

Guidance

MetricGuidePrior guideChange
Revenue$520M-$530M$490M-$500M+$30M-$30M
Adjusted EBITDA$90M-$100M$66M-$78M+$24M-$22M

What drove it

  • Revenue story Testing Services revenue grew 65% YoY to $119.2M, driven by volume growth of 51% to 75,900 tests and the addition of Specialty Oncology revenue following the NavDx acquisition; Patient and Digital Solutions revenue grew 31% YoY to $20.2M.
  • EPS story GAAP EPS grew 1,133% YoY driven by higher revenue and improved margins; adjusted EPS grew 157% YoY driven by revenue growth and disciplined expense management.
  • One-off check Business development and portfolio optimization expense of $5.5M includes costs related to the NavDx acquisition.

The good

  • Testing Services volume increased 51% YoY to 75,900 tests
  • Adjusted EBITDA margin expanded 7 pp YoY to 22%
  • Cash and cash equivalents increased 283% YoY to $250.5M

The bad

  • Cash flow from operations decreased 58% QoQ to $13.0M
  • GAAP net income decreased 82.6% QoQ to $19.3M

The ugly

  • none

Open questions

  • What specific factors caused cash flow from operations to decline 58% sequentially?
  • What is the expected timing and magnitude of the $100M contingent consideration payment for the NavDx acquisition?
Full release

Earnings: CDNA — filed 2026-10-29

CareDx, Inc. (CDNA) · Form 8-K, Item 2.02 · Filed · SEC filing

CareDx Announces Third Quarter 2026 Financial Results

Third Quarter Revenue Growth of 39% to $139 Million

Raises 2026 Revenue Guidance to $520 Million to $530 Million and Adjusted EBITDA Guidance to $90 Million to $100 Million

BRISBANE, Calif. — (BUSINESS WIRE) — CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today reported financial results for the third quarter ended September 30, 2026.

Third Quarter 2026 Financial Highlights

• Revenue of $139 million, an increase of 39% year-over-year

• Testing Services revenue of $119 million, an increase of 65% year-over-year

• Testing Services volume of approximately 75,900, an increase of 51% year-over-year, including contributions following our acquisition of NavDx

• Patient and Digital Solutions revenue of $20 million, an increase of 31% year-over-year

• GAAP net income of $19 million, compared with GAAP net income of $2 million for the third quarter of 2025

• Closed the acquisition of Naveris, Inc. on July 1, 2026 for $160 million in cash consideration and up to $100 million in contingent consideration

• Adjusted EBITDA of $30 million, compared with $15 million for the third quarter of 2025

• Cash flow from operations of $13 million

Recent Business Highlights

• Advanced AlloHeme toward a planned first-quarter 2027 commercial launch and HistoMap Kidney toward broader commercial availability in 2027, with both programs targeting CLIA readiness before year-end

• Published new HistoMap data in Transplantation demonstrating its potential to identify clinically meaningful risk beyond conventional pathology

• Broadened the clinical evidence for NavDx across multiple contexts of use, including a newly published eight-center study of 332 patients evaluating molecular results during the first three months after treatment and two independent Phase II studies exploring radiation de-escalation after surgery and during definitive treatment

• Presented new KOAR registry data demonstrating the potential for AlloSure Kidney to identify patients at greater risk of graft loss or declining kidney function when biopsy findings are difficult to interpret

• Advanced commercial and workflow execution across the portfolio, including continued Epic Aura adoption, more than 5,000 transplant patients registered for the new CareDx patient portal, and the migration of NavDx to the CareDx billing platform

“We delivered another strong quarter of solid execution, with continued growth in Transplant, progress scaling Specialty Oncology, and important advances across our pipeline and clinical evidence, including in Cell Therapy,” said John Hanna, President and Chief Executive Officer of CareDx. “We see significant clinical interest in how molecular information can inform more decisions across a patient’s care journey, while continuing to make our solutions easier for providers to adopt and patients to access. We believe these dynamics create meaningful opportunities for continued profitable growth.”

Third Quarter 2026 Financial Results

Total revenue was $139 million, compared with $100 million in the third quarter of 2025, an increase of 39% year-over-year, driven primarily by growth in Testing Services and Patient and Digital Solutions revenue, including the addition of Specialty Oncology revenue following our acquisition of NavDx.

Testing Services revenue was $119 million, compared with $72 million in the third quarter of 2025, an increase of 65% year-over-year, including $12 million in Specialty Oncology revenue. Testing Services revenue includes $15 million in prior period revenue, compared with $6 million in the third quarter of 2025. Testing Services volume was approximately 75,900, an increase of 51% year-over-year, including contributions from Specialty Oncology. Excluding revenue recognized for tests performed in prior periods, Testing Services revenue increased approximately 58% year-over-year.

Patient and Digital Solutions revenue was $20 million, compared with $15 million in the third quarter of 2025, an increase of 31% year-over-year, driven primarily by continued growth in CareDx Pharmacy services.

As a reminder, the Company completed the divestiture of its Lab Products business on June 30, 2026. Accordingly, the Company’s third quarter 2026 results do not include Lab Products revenue.

GAAP net income was $19 million, compared with GAAP net income of $2 million in the third quarter of 2025. Basic and diluted GAAP net income per share were $0.37 and $0.35, respectively, compared with basic and diluted GAAP net income per share of $0.03 in the third quarter of 2025. GAAP net income margin was approximately 14%, compared with approximately 2% in the third quarter of 2025.

Adjusted EBITDA was $30 million, compared with $15 million in the third quarter of 2025, driven by revenue growth, higher gross profit and disciplined operating expense management. Adjusted EBITDA margin was approximately 22%, compared with approximately 15% in the third quarter of 2025.

2026 Guidance

For the full year 2026, CareDx now expects revenue to be in the range of $520 million to $530 million, compared with its previously disclosed range of $490 million to $500 million. The Company now expects full-year 2026 Adjusted EBITDA to be in the range of $90 million to $100 million, compared with its previously disclosed range of $66 million to $78 million.

About CareDx

CareDx is a leading precision medicine diagnostics company advancing care in transplant, specialty oncology, and cell therapy. Through non-invasive longitudinal molecular biomarker testing, digital health, and patient support solutions, CareDx is dedicated to improving patient outcomes. For more information, please visit www.caredx.com.

Financial statements

Income Statement

Three Months Ended September 30, — (In thousands, except share and per share data)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025
Revenue:
Testing services revenue119,19172,168
Product revenue12,478
Patient and digital solutions revenue20,17115,409
Total revenue139,362100,055
Operating expenses:
Cost of testing services24,68314,705
Cost of product5,629
Cost of patient and digital solutions15,60410,320
Research and development21,32416,769
Sales and marketing31,65024,449
General and administrative37,98928,429
Total operating expenses131,250100,301
Income (loss) from operations8,112-246
Other income:
Interest income, net2,2082,013
Other income (expense), net372-107
Total other income2,5801,906
Income before income taxes10,6921,660
Income tax benefit8,60015
Net income19,2921,675
Net income per share:
Basic0.370.03
Diluted0.350.03
Weighted-average shares used to compute net income (loss) per share:
Basic52,116,05152,507,582
Diluted54,984,98953,736,790

Income Statement

Three Months Ended — (In thousands, except percentages)

Three Months Ended – September 30, 2026Three Months Ended – June 30, 2026Three Months Ended – September 30, 2025
GAAP total revenue139,362131,948100,055
GAAP cost of sales40,28734,96630,654
GAAP gross profit99,07596,98269,401
GAAP gross margin %717469
Stock-based compensation expense309321468
Restructuring costs123
Business development and portfolio optimization expense*311
Acquisition related-amortization of purchased intangibles3,077355947
Non-GAAP gross profit102,46197,96970,939
Non-GAAP gross margin %747471

Income Statement

Year Ended December 31, 2025 — (In thousands)

Year Ended December 31, 2025
GAAP net loss-21,354
Stock-based compensation expense34,864
Acquisition related-amortization of purchased intangibles6,349
Acquisition related fees and expenses204
Change in estimated fair value of contingent consideration703
Tax effect related to amortization of purchased intangibles-431
Impairment of intangible asset2,258
Transformational initiative costs2,824
Restructuring costs890
Litigation settlement expense5,710
Non-GAAP net income32,017
Interest income-9,174
Income tax expense702
Depreciation expense8,667
Other (income) expense, net-524
Adjusted EBITDA31,688

Income Statement

Three Months Ended — (In thousands, except percentages)

Three Months Ended – September 30, 2026Three Months Ended – June 30, 2026Three Months Ended – September 30, 2025
GAAP net income19,292110,6361,675
GAAP net income margin14842
Gain on sale of lab products business-112,966
Stock-based compensation expense9,65510,6548,418
Business development and portfolio optimization expense*5,52711,078
Acquisition related-amortization of purchased intangibles3,8945291,602
Tax effect related to amortization of purchased intangibles54-111
Impairment of intangible asset2,258
Transformational initiative costs524
Restructuring costs530
Non-GAAP net income38,36819,98514,896
Interest income-2,208-1,735-2,013
Income tax (income) expense-8,6003,82896
Depreciation expense3,3082,2862,213
Other (income) expense, net-372440107
Adjusted EBITDA30,49624,80415,299
Revenue139,362131,948100,055
Adjusted EBITDA margin221915

Balance Sheet

(In thousands)

As of – September 30, 2026As of – December 31, 2025
Current assets:
Cash and cash equivalents250,48065,429
Marketable securities111,779
Accounts receivable47,73042,628
Inventory9,14426,705
Prepaid and other current assets13,94310,591
Total current assets321,297257,132
Property and equipment, net27,01132,971
Operating lease right-of-use assets23,54122,760
Marketable securities, non-current24,165
Intangible assets, net139,78131,960
Goodwill121,70940,336
Restricted cash1,410551
Other assets6,7083,353
Total assets641,457413,228
Current liabilities:
Accounts payable10,8089,988
Accrued compensation40,56438,107
Accrued and other liabilities87,60341,754
Total current liabilities138,97589,849
Deferred tax liability536181
Contingent consideration, non-current14,035161
Operating lease liabilities, less current portion20,31619,679
Other liabilities139257
Total liabilities174,001110,127
Stockholders’ equity:
Common stock5250
Additional paid-in capital953,558927,457
Accumulated other comprehensive loss-5,515
Accumulated deficit-486,154-618,891
Total stockholders’ equity467,456303,101
Total liabilities and stockholders’ equity641,457413,228

Cash Flow

From the 10-Q · Nine Months Ended September 30, — ) (in thousands)

Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Operating activities:
Net income (loss)132,737-17,246
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Stock-based compensation30,11226,773
Depreciation and amortization13,91411,136
Impairment of intangible asset and associated construction in progress2,258
Amortization of right-of-use assets4,5174,020
Loss on disposal of asset210
Gain on sale of lab products business-112,966
Revaluation of contingent consideration to estimated fair value547
Non-cash income tax benefit in connection with business acquisition (Note 6)-9,839
Amortization of premium and accretion of discount on marketable securities, net1,4141,493

Forward-Looking Statements... (truncated)rational goals and its expectations and prospects for 2026 and beyond. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, all of which are difficult to predict and many of which are beyond CareDx’s control, that could cause the actual results to differ materially from those projected, including general economic and market factors, and global economic and marketplace uncertainties, among others discussed in CareDx’s filings with the Securities and Exchange Commission (the “SEC”), including, but not limited to, the Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed by CareDx with the SEC on February 25, 2026, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx’s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

Use of Non-GAAP Financial Measures

CareDx has presented in this release certain financial information in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) and also on a non-GAAP basis, including non-GAAP cost of testing services, non-GAAP cost of product, non-GAAP cost of patient and digital solutions, non-GAAP research and development expenses, non-GAAP sales and marketing expenses, non-GAAP general and administrative expenses, non-GAAP other income, net, non-GAAP income tax expense, non-GAAP gross profit, non-GAAP gross margin (%), non-GAAP operating expenses, non-GAAP net income, non-GAAP basic and diluted net income per share, adjusted EBITDA and adjusted EBITDA margin. These non-GAAP financial measures are not meant to be considered superior to or a substitute for financial measures calculated in accordance with GAAP, and investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures as an analytical tool.

We define non-GAAP net income and per share results as the GAAP net income (loss) and per share results excluding the impacts of stock-based compensation expense; acquisition-related amortization of purchased intangible assets and related tax effects; changes in estimated fair value of contingent consideration; litigation settlement expense; business development and portfolio optimization expense; gain on sale of lab product business; and certain other charges presented in the reconciliation in this release. We define adjusted EBITDA as non-GAAP net income before interest income, income tax expense, depreciation expense and other (income) expense, net. We define non-GAAP gross profit and non-GAAP gross margin as GAAP gross profit and GAAP gross margin excluding the impacts of stock-based compensation expense, and acquisition-related amortization of purchased intangible assets included in cost of sales. Non-GAAP gross margin is calculated as non-GAAP gross profit divided by total revenue. Adjusted EBITDA margin is calculated as adjusted EBITDA divided by total revenue. Corporate free cash flow is defined as Cash from Operations less Capital Expenditures.

We are presenting these non-GAAP financial measures to assist investors in assessing our operating results through the eyes of management and because we believe that these measures provide an additional tool for investors to use in comparing our core business operating results over multiple periods where certain items may vary independent of business performance. Management believes this non-GAAP information is useful for investors, when considered in conjunction with CareDx’s GAAP financial statements, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of CareDx’s operating results as reported under GAAP. These non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. These non-GAAP financial measures are not necessarily comparable to similarly titled measures presented by other companies. A reconciliation between GAAP and non-GAAP financial information is provided immediately following the financial tables. A reconciliation of the forecasted range for adjusted EBITDA for 2026 is not included in this release due to the number of variables in the projected range and because we are currently unable to quantify accurately certain amounts that would be required to be included in the U.S. GAAP measure or the individual adjustments for such reconciliation.

CareDx, Inc.

Media Relations

Natasha Moshirian Wagner nwagner@CareDx.com

Investor Relations

Nina Deka investor@CareDx.com

CareDx, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

(In thousands, except share and per share data)

CareDx, Inc.

Condensed Consolidated Balance Sheets

(Unaudited)

(In thousands)

CareDx, Inc.

Reconciliation of GAAP to Non-GAAP Financial Measures

(Unaudited)

(In thousands)

* Business development and portfolio optimization expense primarily includes legal, consulting, financial advisory, due diligence, and other transaction-related costs incurred in connection with business development activities, including the sale of our lab products business and acquisition of Naveris, Inc.

CareDx, Inc.

GAAP and Non-GAAP Operating Expenses

(Unaudited)

(In thousands)

CareDx, Inc.

Reconciliation of GAAP to Non-GAAP Gross Profit and Gross Margin

(Unaudited)... (truncated)ept percentages)

* Business development and portfolio optimization expense primarily includes legal, consulting, financial advisory, due diligence, and other transaction-related costs incurred in connection with business development activities, including the sale of our lab products business and acquisition of Naveris, Inc.

CareDx, Inc.

Reconciliation of GAAP to Non-GAAP Financial Measures

(Unaudited)

(In thousands, except share and per share data)

* Business development and portfolio optimization expense primarily includes legal, consulting, financial advisory, due diligence, and other transaction-related costs incurred in connection with business development activities, including the sale of our lab products business and acquisition of Naveris, Inc.

CareDx, Inc.

Reconciliation of Non-GAAP to Adjusted EBITDA

(Unaudited)

(In thousands)

* Business development and portfolio optimization expense primarily includes legal, consulting, financial advisory, due diligence, and other transaction-related costs incurred in connection with business development activities, including the sale of our lab products business and acquisition of Naveris, Inc.

CareDx, Inc.

Reconciliation of Non-GAAP to Adjusted EBITDA

(Unaudited)

(In thousands)

CareDx, Inc.

Reconciliation of GAAP Net Income Margin to Adjusted EBITDA Margin

(Unaudited)

(In thousands, except percentages)

* Business development and portfolio optimization expense primarily includes legal, consulting, financial advisory, due diligence, and other transaction-related costs incurred in connection with business development activities, including the sale of our lab products business and acquisition of Naveris, Inc.

CareDx, Inc.

Net Cash Provided by Operating Activities Reconciliation to Free Cash Flow

(Unaudited)

(In thousands)

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.